Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Pancreatic Ductal Adenocarcinoma remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 667 matched trial records and 436 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07701486 | Albumin-Bound Paclitaxel + Gemcitabine Hydrochloride + Zabilugene Almadenorepvec | Phase 1/2; Not yet recruiting | Theriva Biologics, Inc. | Spain | Safety and tolerability (From enrolment up to 30-days from the last dose of study intervention); Pharmacokinetics (PK) of VCN-01 (From enrollment up to 30 days from the last dose of study intervention) | 2027-08-01 |
| NCT07702292 | [68Ga]Ga-OncoFAP | Phase 2; Recruiting | Blue Earth Diagnostics Ltd. | Netherlands, Italy | Assess the diagnostic performance of [68Ga]BED003 in the peritoneum. (Until completion of follow-up procedures, up to 42 days post injection.) | 2028-02-01 |
| NCT07699757 | Albumin-Bound Paclitaxel + Sintilimab + Carboplatin | Phase 1; Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | China | DLTs (21 days for NSCLC cohorts; 28 days for PDAC cohorts); AEs (Up to approximately 3 years) | 2029-04-01 |
| NCT07694973 | Inavolisib | Phase 2; Not yet recruiting | Fudan University | China | Objective response rate (ORR) (CR and PR require confirmatory CT or MRI repeat assessment at least 4 weeks…) | 2028-06-29 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A First-in-human Open Label Phase Ia/Ib, Multicenter/Multiregional, Dose Escalation Study of BI 765883 Administered Intravenously as Monotherapy and in Combination With Gemcitabine and Nab-paclitaxel in Unselected Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) or Patients With PDAC Who Have Relapsed After Post-surgery Adjuvant Therapy (Phase 1): the indexed record reports Occurrence of Dose-Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period for the Determination of the Maximum Tolerated Dose (MTD) = 3 Participants; -; Occurrence of Dose-Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period for the Determination of the Maximum Tolerated Dose (MTD) = 0 Participants.
- Phase 2 Randomized Trial of Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Pancreatic Adenocarcinoma (Phase 2): the indexed record reports Other (Not Including Serious) Adverse Events = 0 Participants; -; -.
- Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (Phase 3): the indexed record reports mOS(overall population) = 6.7 month; mOS(overall population) = 13.2 month.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Albumin-Bound Paclitaxel (Approved; Tubulin), Gemcitabine Hydrochloride (Approved; DNA x RNRs), Zabilugene Almadenorepvec (Phase 2; Hyaluronic acid), [68Ga]Ga-OncoFAP (Phase 2; FAP), Sintilimab (Approved; PD-1). Company & Deal Intelligence records identify sponsor context for Theriva Biologics, Inc. (TOVX), Blue Earth Diagnostics Ltd., Haisco Pharmaceutical Group Co., Ltd. (002653), Fudan University. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Pancreatic Ductal Adenocarcinoma has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
